Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Melanoma 55Neoplasm Metastasis 17Carcinoma, Renal Cell 15Carcinoma, Non-Small-Cell Lung 15Neoplasms 14Pancreatic Neoplasms 11Uveal Melanoma 10Prostatic Neoplasms 10Leukemia, Myeloid, Acute 9Squamous Cell Carcinoma of Head and Neck 7Sarcoma 7Myelodysplastic Syndromes 7Lymphoma 7Lung Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Colorectal Neoplasms 7Carcinoma, Hepatocellular 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Carcinoma, Transitional Cell 6Breast Neoplasms 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Recurrence 5Myeloproliferative Disorders 5Multiple Myeloma 5Lymphoma, Non-Hodgkin 5Hematologic Neoplasms 5Glioblastoma 5Urinary Bladder Neoplasms 4Ovarian Neoplasms 4

Interventions

entinostat 1Pharmacogenomic Testing 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Anatomic Stage III Breast Cancer AJCC v8 × Ipilimumab × Clear all
NCT02453620 2026-04-13

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
57 enrolled
BreastOther solid neoplasm

Anatomic Stage III Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡